EyePoint (EYPT) Revenue (2010 - 2026)
EyePoint (EYPT) posted Revenue of $696000.0 for Q1 2026, up 12.26% sequentially from $620000.0 in Q4 2025, and down 97.15% YoY from $24.5 million in Q1 2025.
Analysis
EyePoint (EYPT) Revenue (2010 - 2026) Analysis & Trends
EyePoint has reported Revenue for 17 years, with the latest figure at $696000.0 in Q1 2026.
- Quarterly Revenue fell 97.15% year-over-year to $696000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 86.41% YoY) and the FY2025 annual result came in at $31.4 million, down 27.5% from the prior year.
- Revenue climbed to $696000.0 in Q1 2026 per EYPT's latest filing, from $620000.0 in the prior quarter.
- Over five years, Revenue peaked at $24.5 million in Q1 2025 and troughed at $620000.0 in Q4 2025.
- A 5-year average of $9.6 million and a median of $10.0 million in 2022 frame the typical range for Revenue.
- The sharpest annual moves came in 2025 and 2026: Revenue surged 109.29% in 2025, then sank 97.15% in 2026.
- Over 5 years, Revenue stood at $10.5 million in 2022, then soared by 33.18% to $14.0 million in 2023, then dropped by 17.39% to $11.6 million in 2024, then tumbled by 94.65% to $620000.0 in 2025, then rose by 12.26% to $696000.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $696000.0, $620000.0, and $966000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 425.49 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 507,000.00 |
| Mar 31, 2026 | 696,000.00 |
| Dec 31, 2025 | 620,000.00 |
| Sep 30, 2025 | 966,000.00 |
| Jun 30, 2025 | 5.33 Mn |
| Mar 31, 2025 | 24.45 Mn |
| Dec 31, 2024 | 11.59 Mn |
| Sep 30, 2024 | 10.52 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Mar 31, 2024 | 11.68 Mn |
| Dec 31, 2023 | 14.03 Mn |
| Sep 30, 2023 | 15.20 Mn |
| Jun 30, 2023 | 9.11 Mn |
| Mar 31, 2023 | 7.68 Mn |
| Dec 31, 2022 | 10.53 Mn |
| Sep 30, 2022 | 10.01 Mn |
| Jun 30, 2022 | 11.57 Mn |
| Mar 31, 2022 | 9.29 Mn |
| Dec 31, 2021 | 11.54 Mn |
| Sep 30, 2021 | 9.06 Mn |